Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 01, 2025 17:04 ET | Source: Coherus BioSciences, Inc.

Coherus to Participate in Upcoming Investor Conferences

REDWOOD CITY, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that the company will be webcasting its participation in the upcoming...
April 28, 2025 10:10 ET | Source: Coherus BioSciences, Inc.

Coherus Presents Promising Early Clinical Data from Phase 1 Dose Expansion Study of CHS-114 in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma at AACR 2025

– CHS-114 demonstrates clinical efficacy and proof of mechanism in HNSCC in combination with toripalimab – – Confirmed partial response in heavily pretreated PD-1 refractory patient supports...
April 14, 2025 08:00 ET | Source: Coherus BioSciences, Inc.

Coherus Completes Strategic Transformation with Successful Divestiture of UDENYCA® Franchise

– $250 million post-close cash balance extends cash runway over two years into 2027, funding pipeline development through key data catalysts – – Coherus to focus exclusively on its innovative novel...
April 01, 2025 08:00 ET | Source: Coherus BioSciences, Inc.

Coherus Announces Repurchase of Approximately $170 Million of Convertible Notes

– Remaining $60 Million of outstanding convertible notes to be repurchased post-close of pending UDENYCA divestiture – REDWOOD CITY, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences,...
March 25, 2025 16:30 ET | Source: Coherus BioSciences, Inc.

Coherus to Present Data from a Phase 1 Dose Expansion Study of CHS-114, a Cytolytic Antibody Targeting Chemokine Receptor 8 (CCR8), at the 2025 American Association for Cancer Research (AACR) Annual Meeting

REDWOOD CITY, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS), a commercial-stage innovative oncology company, today announced that an abstract...
March 10, 2025 16:12 ET | Source: Coherus BioSciences, Inc.

Coherus BioSciences Reports Fourth Quarter, Full Year 2024 Financial Results and Provides Business Update

– Annual net revenue increased 4% to $267.0 million in 2024, despite significant divestitures –– UDENYCA® net revenue increased 62% year-over-year –– LOQTORZI® net revenue increased 29%...
March 03, 2025 08:30 ET | Source: Coherus BioSciences, Inc.

Coherus to Report Fourth Quarter and Full Year 2024 Financial Results on March 10, 2025

REDWOOD CITY, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that its fourth quarter and full year 2024 financial results will be...
February 24, 2025 09:08 ET | Source: Coherus BioSciences, Inc.

Coherus Management to Participate at the 45th Annual TD Cowen Health Care Conference

REDWOOD CITY, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that senior management will participate in a fireside chat presentation at...
January 22, 2025 07:00 ET | Source: Coherus BioSciences, Inc.

Coherus Presents Final Phase 2 Clinical Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025

– Casdozokitug, in combination with atezolizumab/bevacizumab, final data demonstrate durability of response and improvement in depth of response including a 17.2% complete response rate – – Antitumor...
January 08, 2025 08:00 ET | Source: Coherus BioSciences, Inc.

Coherus Management to Present at the 43rd Annual J.P. Morgan Healthcare Conference

REDWOOD CITY, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that senior management will present at the 43rd Annual J.P. Morgan...